Ankle Foot Orthosis Comparative Effect

NCT03901053 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

The proposed effort is designed to support evidence-based practice and optimal care by evaluating how the form, fit and function of two commercially available carbon fiber custom fit braces (Orthoses) influences outcomes following extremity injury. Early data suggests that custom fit carbon fiber braces can significantly improve function following severe lower leg injuries. The proposed study will provide evidence that can be used by clinicians to guide their practice, including care for service members, veterans and civilians who have experienced a high-energy traumatic injury to their lower leg.

Conditions

  • Foot Injuries and Disorders

Interventions

DEVICE

Reaktiv AFO

This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.

DEVICE

PhatBrace AFO

Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.

Sponsors & Collaborators

  • Minneapolis Veterans Affairs Medical Center

    collaborator FED
  • Walter Reed National Military Medical Center

    collaborator FED
  • Henry M. Jackson Foundation for the Advancement of Military Medicine

    collaborator OTHER
  • Center for Veterans Research and Education

    collaborator OTHER
  • University of Delaware

    collaborator OTHER
  • Johns Hopkins Bloomberg School of Public Health

    collaborator OTHER
  • Jason Wilken

    lead OTHER

Principal Investigators

  • Jason M. Wilken, PT, PhD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-27
Primary Completion
2023-12-18
Completion
2023-12-18
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901053 on ClinicalTrials.gov